List of Tables
Table 1. Cancer Immunotherapy Drug Market Trends
Table 2. Cancer Immunotherapy Drug Market Drivers & Opportunity
Table 3. Cancer Immunotherapy Drug Market Challenges
Table 4. Cancer Immunotherapy Drug Market Restraints
Table 5. Global Cancer Immunotherapy Drug Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Cancer Immunotherapy Drug Revenue Market Share by Company (2019-2024)
Table 7. Global Cancer Immunotherapy Drug Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Cancer Immunotherapy Drug Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Cancer Immunotherapy Drug Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Cancer Immunotherapy Drug Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Cancer Immunotherapy Drug Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Cancer Immunotherapy Drug
Table 13. Global Cancer Immunotherapy Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapy Drug as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Cancer Immunotherapy Drug Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Cancer Immunotherapy Drug Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Cancer Immunotherapy Drug Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Cancer Immunotherapy Drug Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Cancer Immunotherapy Drug Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Cancer Immunotherapy Drug Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Cancer Immunotherapy Drug Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Cancer Immunotherapy Drug Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Cancer Immunotherapy Drug Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Cancer Immunotherapy Drug Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Cancer Immunotherapy Drug Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Cancer Immunotherapy Drug Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Cancer Immunotherapy Drug Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Cancer Immunotherapy Drug Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Cancer Immunotherapy Drug Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Cancer Immunotherapy Drug Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Cancer Immunotherapy Drug Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Cancer Immunotherapy Drug Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Cancer Immunotherapy Drug Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Cancer Immunotherapy Drug Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Cancer Immunotherapy Drug Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Cancer Immunotherapy Drug Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Cancer Immunotherapy Drug Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Cancer Immunotherapy Drug Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Cancer Immunotherapy Drug Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Cancer Immunotherapy Drug Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Cancer Immunotherapy Drug Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Cancer Immunotherapy Drug Sales Value by Region (2019-2024) & (%)
Table 44. Global Cancer Immunotherapy Drug Sales Value by Region (2025-2030) & (%)
Table 45. Global Cancer Immunotherapy Drug Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Cancer Immunotherapy Drug Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Cancer Immunotherapy Drug Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Cancer Immunotherapy Drug Sales Volume by Region (2019-2024) & (%)
Table 49. Global Cancer Immunotherapy Drug Sales Volume by Region (2025-2030) & (%)
Table 50. Global Cancer Immunotherapy Drug Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Cancer Immunotherapy Drug Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Cancer Immunotherapy Drug Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Cancer Immunotherapy Drug Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Cancer Immunotherapy Drug Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Cancer Immunotherapy Drug Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Cancer Immunotherapy Drug Sales Volume, (2025-2030) & (K Units)
Table 57. Autolus Therapeutics plc Company Information
Table 58. Autolus Therapeutics plc Introduction and Business Overview
Table 59. Autolus Therapeutics plc Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Autolus Therapeutics plc Cancer Immunotherapy Drug Product Offerings
Table 61. Autolus Therapeutics plc Recent Development
Table 62. BeiGene Company Information
Table 63. BeiGene Introduction and Business Overview
Table 64. BeiGene Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. BeiGene Cancer Immunotherapy Drug Product Offerings
Table 66. BeiGene Recent Development
Table 67. bluebird bio, Inc. Company Information
Table 68. bluebird bio, Inc. Introduction and Business Overview
Table 69. bluebird bio, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. bluebird bio, Inc. Cancer Immunotherapy Drug Product Offerings
Table 71. bluebird bio, Inc. Recent Development
Table 72. Bristol-Myers Squibb Company Information
Table 73. Bristol-Myers Squibb Introduction and Business Overview
Table 74. Bristol-Myers Squibb Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Bristol-Myers Squibb Cancer Immunotherapy Drug Product Offerings
Table 76. Bristol-Myers Squibb Recent Development
Table 77. Celgene Corporation Company Information
Table 78. Celgene Corporation Introduction and Business Overview
Table 79. Celgene Corporation Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Celgene Corporation Cancer Immunotherapy Drug Product Offerings
Table 81. Celgene Corporation Recent Development
Table 82. AstraZeneca plc Company Information
Table 83. AstraZeneca plc Introduction and Business Overview
Table 84. AstraZeneca plc Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. AstraZeneca plc Cancer Immunotherapy Drug Product Offerings
Table 86. AstraZeneca plc Recent Development
Table 87. Gilead Sciences, Inc. Company Information
Table 88. Gilead Sciences, Inc. Introduction and Business Overview
Table 89. Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Gilead Sciences, Inc. Cancer Immunotherapy Drug Product Offerings
Table 91. Gilead Sciences, Inc. Recent Development
Table 92. Incyte Corporation Company Information
Table 93. Incyte Corporation Introduction and Business Overview
Table 94. Incyte Corporation Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Incyte Corporation Cancer Immunotherapy Drug Product Offerings
Table 96. Incyte Corporation Recent Development
Table 97. Jiangsu Hengrui Medicine Company Information
Table 98. Jiangsu Hengrui Medicine Introduction and Business Overview
Table 99. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product Offerings
Table 101. Jiangsu Hengrui Medicine Recent Development
Table 102. Juno Pharmaceuticals Pty Ltd. Company Information
Table 103. Juno Pharmaceuticals Pty Ltd. Introduction and Business Overview
Table 104. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Offerings
Table 106. Juno Pharmaceuticals Pty Ltd. Recent Development
Table 107. Medimmune, LLC Company Information
Table 108. Medimmune, LLC Introduction and Business Overview
Table 109. Medimmune, LLC Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Medimmune, LLC Cancer Immunotherapy Drug Product Offerings
Table 111. Medimmune, LLC Recent Development
Table 112. Merck & Co., Inc. Company Information
Table 113. Merck & Co., Inc. Introduction and Business Overview
Table 114. Merck & Co., Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Merck & Co., Inc. Cancer Immunotherapy Drug Product Offerings
Table 116. Merck & Co., Inc. Recent Development
Table 117. Novartis AG Company Information
Table 118. Novartis AG Introduction and Business Overview
Table 119. Novartis AG Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Novartis AG Cancer Immunotherapy Drug Product Offerings
Table 121. Novartis AG Recent Development
Table 122. Pfizer, Inc. Company Information
Table 123. Pfizer, Inc. Introduction and Business Overview
Table 124. Pfizer, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 125. Pfizer, Inc. Cancer Immunotherapy Drug Product Offerings
Table 126. Pfizer, Inc. Recent Development
Table 127. Roche Holding AG Company Information
Table 128. Roche Holding AG Introduction and Business Overview
Table 129. Roche Holding AG Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 130. Roche Holding AG Cancer Immunotherapy Drug Product Offerings
Table 131. Roche Holding AG Recent Development
Table 132. Key Raw Materials Lists
Table 133. Raw Materials Key Suppliers Lists
Table 134. Cancer Immunotherapy Drug Downstream Customers
Table 135. Cancer Immunotherapy Drug Distributors List
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Immunotherapy Drug Product Picture
Figure 2. Global Cancer Immunotherapy Drug Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Cancer Immunotherapy Drug Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Cancer Immunotherapy Drug Sales Volume (2019-2030) & (K Units)
Figure 5. Global Cancer Immunotherapy Drug Sales Price (2019-2030) & (US$/Unit)
Figure 6. Cancer Immunotherapy Drug Report Years Considered
Figure 7. Global Cancer Immunotherapy Drug Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Cancer Immunotherapy Drug Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Cancer Immunotherapy Drug Revenue in 2023
Figure 10. Cancer Immunotherapy Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. PD-1 Inhibitor Picture
Figure 12. PDL-1 Inhibitor Picture
Figure 13. T-Cell Stimulant Picture
Figure 14. CTLA Antibody Picture
Figure 15. Global Cancer Immunotherapy Drug Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Cancer Immunotherapy Drug Sales Value Market Share by Type, 2023 & 2030
Figure 17. Global Cancer Immunotherapy Drug Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 18. Global Cancer Immunotherapy Drug Sales Volume Market Share by Type, 2023 & 2030
Figure 19. Global Cancer Immunotherapy Drug Price by Type (2019-2030) & (US$/Unit)
Figure 20. Product Picture of Hospital
Figure 21. Product Picture of Clinic
Figure 22. Product Picture of Others
Figure 23. Global Cancer Immunotherapy Drug Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 24. Global Cancer Immunotherapy Drug Sales Value Market Share by Application, 2023 & 2030
Figure 25. Global Cancer Immunotherapy Drug Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 26. Global Cancer Immunotherapy Drug Sales Volume Market Share by Application, 2023 & 2030
Figure 27. Global Cancer Immunotherapy Drug Price by Application (2019-2030) & (US$/Unit)
Figure 28. North America Cancer Immunotherapy Drug Sales Value (2019-2030) & (US$ Million)
Figure 29. North America Cancer Immunotherapy Drug Sales Value by Country (%), 2023 VS 2030
Figure 30. Europe Cancer Immunotherapy Drug Sales Value (2019-2030) & (US$ Million)
Figure 31. Europe Cancer Immunotherapy Drug Sales Value by Country (%), 2023 VS 2030
Figure 32. Asia Pacific Cancer Immunotherapy Drug Sales Value (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Cancer Immunotherapy Drug Sales Value by Country (%), 2023 VS 2030
Figure 34. South America Cancer Immunotherapy Drug Sales Value (2019-2030) & (US$ Million)
Figure 35. South America Cancer Immunotherapy Drug Sales Value by Country (%), 2023 VS 2030
Figure 36. Middle East & Africa Cancer Immunotherapy Drug Sales Value (2019-2030) & (US$ Million)
Figure 37. Middle East & Africa Cancer Immunotherapy Drug Sales Value by Country (%), 2023 VS 2030
Figure 38. Key Countries/Regions Cancer Immunotherapy Drug Sales Value (%), (2019-2030)
Figure 39. Key Countries/Regions Cancer Immunotherapy Drug Sales Volume (%), (2019-2030)
Figure 40. United States Cancer Immunotherapy Drug Sales Value, (2019-2030) & (US$ Million)
Figure 41. United States Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
Figure 42. United States Cancer Immunotherapy Drug Sales Value by Application (%), 2023 VS 2030
Figure 43. Europe Cancer Immunotherapy Drug Sales Value, (2019-2030) & (US$ Million)
Figure 44. Europe Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
Figure 45. Europe Cancer Immunotherapy Drug Sales Value by Application (%), 2023 VS 2030
Figure 46. China Cancer Immunotherapy Drug Sales Value, (2019-2030) & (US$ Million)
Figure 47. China Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
Figure 48. China Cancer Immunotherapy Drug Sales Value by Application (%), 2023 VS 2030
Figure 49. Japan Cancer Immunotherapy Drug Sales Value, (2019-2030) & (US$ Million)
Figure 50. Japan Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
Figure 51. Japan Cancer Immunotherapy Drug Sales Value by Application (%), 2023 VS 2030
Figure 52. South Korea Cancer Immunotherapy Drug Sales Value, (2019-2030) & (US$ Million)
Figure 53. South Korea Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
Figure 54. South Korea Cancer Immunotherapy Drug Sales Value by Application (%), 2023 VS 2030
Figure 55. Southeast Asia Cancer Immunotherapy Drug Sales Value, (2019-2030) & (US$ Million)
Figure 56. Southeast Asia Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
Figure 57. Southeast Asia Cancer Immunotherapy Drug Sales Value by Application (%), 2023 VS 2030
Figure 58. India Cancer Immunotherapy Drug Sales Value, (2019-2030) & (US$ Million)
Figure 59. India Cancer Immunotherapy Drug Sales Value by Type (%), 2023 VS 2030
Figure 60. India Cancer Immunotherapy Drug Sales Value by Application (%), 2023 VS 2030
Figure 61. Cancer Immunotherapy Drug Industrial Chain
Figure 62. Cancer Immunotherapy Drug Manufacturing Cost Structure
Figure 63. Channels of Distribution (Direct Sales, and Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
